CASIRIVIMAB,IMDEVIMAB

Casirivimab and imdevimab is an antiviral medication belonging to the monoclonal antibody class. The FDA approved it on November 21, 2020, for the treatment of acute COVID-19 infection.

Casirivimab + Imdevimab is available as an injection. It is used to treat patients with confirmed acute COVID-19 infection. It is also indicated to prevent acute COVID-19 infection. Acute covid-19 infection is caused by a virus called coronavirus. People can get COVID-19 through contact with another person who has the virus.

Casirivimab + Imdevimab is given as an infusion into your vein that lasts for 20 to 30 minutes, or it can be given as a subcutaneous (under the skin) injection. This injection will be given to you by a doctor or nurse who is experienced in the use of this type of treatment. They will monitor you closely while you are being given this medicine. Do not self-administer this medicine.

The side effects of Casirivimab + Imdevimab are injection site reactions like swelling, redness, and infusion reactions such as skin rash, nausea, vomiting, difficulty breathing, swelling in the face, feet, and hands, and cough.

This drug is indicated to cause severe hypersensitivity and infusion reactions like fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g., atrial fibrillation, tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions (e.g., pre-syncope, syncope), dizziness, and diaphoresis. Inform your physician immediately if you experience any of these symptoms after receiving the injection.

Do not take Casirivimab + Imdevimab if you are allergic to Casirivimab + Imdevimab or any other ingredients. This medicine can cause allergic reactions following the infusion or injection; notify your physician immediately if you face any of the infusion reactions. Before you take this injection, inform your doctor if you have been vaccinated against COVID infection. Inform your doctor if you are pregnant or breastfeeding before initiating the treatment. Inform your healthcare provider about all your medicines, including prescription, over-the-counter, nutritional, vitamin supplements, and herbal products. Certain medications interact with Casirivimab + Imdevimab, reducing their effectiveness by causing undesirable side effects.

Store in a refrigerator between 2°C and 8°C. Do not freeze. Protect the medicine from light and excessive moisture. Keep out of reach of children and pets. If you miss a scheduled dose, inform your healthcare professional immediately to reschedule. Self-isolate and practise infection control measures including wearing a mask, maintaining social distance, avoiding sharing personal items, cleaning and disinfecting high-touch surfaces, and frequent handwashing. The most common side effects may include infusion-related reactions such as swelling in the hands, face, and feet, skin rash, breathing difficulties, cough, abdominal pain, and chest pain. Injection site reactions including swelling and redness at the injection site can also occur.

fact sheet for health care providers emergency use authorization (eua) of regen-cov tm (Casirivimab with Imdevimab); (Revised January 2022.) Accessed May 22, 2023 https://www.fda.gov/media/145611/download Paroma Deb et al; An update to the monoclonal antibody as a therapeutic option against COVID-19, [Published on Apr 2021], [Accessed May 22, 2023] https://www.sciencedirect.com/science/article/pii/S2590053621000197 John P Manis; Overview of therapeutic monoclonal antibodies, [Published on May 2021], [Accessed May 22, 2023], https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-antibodies#H395449287